Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,742 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07016438Recruiting
Study of PAL-222 for stubborn skin ulcers
This trial tests a new treatment, PAL-222, for skin ulcers that haven't improved much after 4 weeks of standard care. It aims to see if PAL-222 can help these wounds heal better.
Kyoto, Shogoin-kawahara-cho, Sakyo-ku, KyotoAges 20 years+ - NCT07022288Recruiting
Study of La Roche-Posay cream for mild facial eczema
This study tests whether a specific soothing moisturizer (La Roche-Posay B5 cream) helps people with mild, stable facial eczema. It is a simple, low-risk trial using a cream you can apply at home.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07021963RecruitingPhase 2
Long-term safety study of HRS-1893 for hypertrophic cardiomyopathy
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
Beijing, Beijing MunicipalityAges 18–85 - NCT07023315RecruitingPhase 3
Study of cadonilimab plus SOX before and after surgery for stomach cancer
This trial tests if adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery can help treat stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this combination improves outcomes for patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT06966154RecruitingPhase 1/Phase 2
Tislelizumab with golidocitinib and selinexor for NK/T-cell lymphoma
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
Shanghai, ShangaiAges 18 years+ - NCT05518253RecruitingPhase 1
CAR-T treatment for CD70-positive advanced solid tumors
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hangzhou, ZhejiangAges 18 years+ - NCT07011056RecruitingPhase 3
Study of a new drug for diffuse large B-cell lymphoma
This trial tests a new drug called Purinostat Mesylate for people with diffuse large B-cell lymphoma (a type of blood cancer) whose cancer has come back or not responded after at least two prior treatments. It aims to see if the drug can help shrink or control the cancer.
Chengdu, SichuanAges 18 years+ - NCT07010094Recruiting
Shockwave balloons for hardened heart artery blockages
This trial tests a special balloon that uses shock waves to crack calcium in heart arteries, making it easier to place a stent. It is for people with chest pain or signs of heart strain due to a single, severely blocked artery with dense calcium.
Fujian, XiamenAges 18–85 - NCT07006012Recruiting
Study of RGL-305 for lymphoma with minimal residual disease
This trial tests if a new treatment called RGL-305 can help people with lymphoma who still have tiny amounts of cancer cells left after previous treatment. It is for those whose disease has responded to prior therapy but is not completely gone at the genetic level.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07004673Recruiting
PET/MR imaging for carotid artery plaque risk
This trial uses special PET/MR scans to look at fatty buildup in your neck arteries to see which ones might be dangerous. It could help doctors better understand your stroke risk and choose the right treatment.
Shanghai, Shanghai MunicipalityAges Any age - NCT07006389Enrolling by invitation
Shock wave therapy for plantar fasciitis follow-up study
This study looks at how well shock wave therapy works for people with plantar fasciitis that hasn't improved with other treatments. If you've already had shock wave therapy 3 to 6 months ago, your experience could help doctors understand what makes the treatment effective.
IstanbulAges 18 years+ - NCT07003074RecruitingPhase 3
New drug TQB2102 vs standard therapy for HER2+ breast cancer
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Hefei, AnhuiAges 18–75 - NCT06997497RecruitingPhase 3
Study of Calderasib with other drugs for colorectal cancer
This trial tests a new drug called Calderasib combined with targeted therapy or chemotherapy for people with advanced colorectal cancer that has a specific genetic change (KRAS G12C mutation). It may be an option for those who have not had prior treatment for advanced disease.
Phoenix, ArizonaAges 18 years+ - NCT06994650RecruitingPhase 3
Study of HRS9531 for sleep apnea and obesity
This trial tests an injection called HRS9531 to see if it helps people with obstructive sleep apnea (OSA) and obesity who already use a CPAP or similar breathing device. It may help by reducing weight and improving breathing during sleep.
Beijing, Beijing MunicipalityAges 18–75 - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT07000682RecruitingEarly Phase 1
UTAA91 injection for systemic sclerosis study
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
Wuhan, HubeiAges 18 years+ - NCT07001956RecruitingEarly Phase 1
UTAA91 injection for difficult rheumatoid arthritis
This trial tests a new injection called UTAA91 for people with hard-to-treat rheumatoid arthritis. It's for those who have tried standard treatments without success.
Wuhan, HubeiAges 18 years+ - NCT06945523RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced lung cancer
This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.
Wuhan, HubeiAges 18 years+ - NCT06992713RecruitingPhase 1
Study of H1710 for advanced solid tumors
This trial tests a new drug called H1710 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if H1710 is safe and effective.
Nanjing, JiangsuAges 18–75 - NCT06983041Recruiting
Vaginal cooling device for yeast infection treatment
This trial tests a new vaginal cooling device to treat yeast infections. It may help relieve symptoms like itching, burning, or irritation without medication.
Jacksonville, FloridaAges 22–49 - NCT06982885Recruiting
AI-assisted imaging study for colorectal lesions
This study tests whether artificial intelligence can help doctors see colorectal lesions more clearly using special advanced imaging. If you have a colorectal lesion, this trial may help improve diagnosis.
Changchun, JilinAges Any age - NCT06973031Recruiting
Testing a new system for treating atrial fibrillation
This trial tests a new device that uses pulsed electric fields to treat atrial fibrillation (AF), a type of irregular heartbeat. It aims to see if this approach is safe and effective for people with AF that comes and goes or lasts for a short time.
KaiserslauternAges 18–80 - NCT06974929RecruitingPhase 1/Phase 2
Study of HRS-6209 combinations for breast cancer
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,742 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.